Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Regulus Therapeutics stock
Learn how to easily invest in Regulus Therapeutics stock.
Regulus Therapeutics Inc is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 25 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Regulus Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RGLS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Regulus Therapeutics stock price (NASDAQ: RGLS)Use our graph to track the performance of RGLS stocks over time.
Regulus Therapeutics shares at a glance
|Latest market close||$2.10|
|52-week range||$0.16 - $0.89|
|50-day moving average||$0.24|
|200-day moving average||$0.35|
|Wall St. target price||$1.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.28|
Buy Regulus Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Regulus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Regulus Therapeutics price performance over time
|1 week (2022-06-24)||772.82%|
|1 month (2022-05-28)||N/A|
|3 months (2022-04-01)||545.96%|
|6 months (2021-12-29)||552.99%|
|1 year (2021-07-01)||154.39%|
|2 years (2020-07-01)||195.77%|
|3 years (2019-07-01)||52.17%|
|5 years (2017-06-30)||113.07%|
Regulus Therapeutics financials
|Revenue TTM||$5 million|
|Gross profit TTM||$-17,794,000|
|Return on assets TTM||-35.44%|
|Return on equity TTM||-74.69%|
|Market capitalisation||$35.1 million|
TTM: trailing 12 months
Regulus Therapeutics share dividends
We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.
Have Regulus Therapeutics's shares ever split?
Regulus Therapeutics's shares were split on a 1:12 basis on 3 October 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.
Regulus Therapeutics share price volatility
Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.16 up to $0.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 2.167. This would suggest that Regulus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Regulus Therapeutics overview
Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .
Regulus Therapeutics in the news
Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK
Frequently asked questionsWhat percentage of Regulus Therapeutics is owned by insiders or institutions?
Currently 4.245% of Regulus Therapeutics shares are held by insiders and 45.232% by institutions. How many people work for Regulus Therapeutics?
Latest data suggests 25 work at Regulus Therapeutics. When does the fiscal year end for Regulus Therapeutics?
Regulus Therapeutics's fiscal year ends in December. Where is Regulus Therapeutics based?
Regulus Therapeutics's address is: 4224 Campus Point Court, San Diego, CA, United States, 92121 What is Regulus Therapeutics's ISIN number?
Regulus Therapeutics's international securities identification number is: US75915K2006 What is Regulus Therapeutics's CUSIP number?
Regulus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75915K101
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert